Use of hyoscine as an adjuvant treatment on shortening the time of abortion induction in second trimester: randomized controlled clinical trial

ABSTRACT
Objective. The aim of this study was to determine whether using hyoscine as an adjuvant treatment with vaginal misoprostol versus vaginal misoprostol only in the induction of abortion in the second trimester can shorten the time of abortion and therefore the duration of hospital stay.
Materials and Methods. This study was a randomized controlled trial conducted on 40 women underwent induction of abortion between 13 and 24 weeks with positive fetal pulsation during the period from December 2022 until June 2023. Patients were randomized into two equal groups as follows: group I included 20 patients who were given only vaginal misoprostol 400 µg, and group II included 20 patients in which women were given vaginal misoprostol 400 µg plus intramuscular administration of hyoscine N-butyl bromide.
Results. There was a statistically significant shorter mean time of abortion induction (hours) of 19.00±8.95 with a P-value (p = 0.029) & hospital stay (days) of 1.65 ± 1.13 with a P-value (p = 0.031) in the intervention group compared to the control group 35.48 ± 16.60 and 2.85 ± 1.43 respectively. According to oxytocin infusion, there was a higher frequency of oxytocin infusion in the control group of 4 women (20%), while there was no oxytocin infusion in the intervention group, with a p-value (p = 0.035).
Conclusions. In comparison to misoprostol alone, we found that hyoscine N-butyl bromide plus misoprostol significantly shortens the time required to induce an abortion in the second trimester without the requirement for an oxytocin infusion and reduces the length of hospital stay.